Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Monte Rosa Therapeutics is raising $96,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Markus Warmuth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Monte Rosa Therapeutics

Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.

To learn more about Monte Rosa Therapeutics, visit http://www.monterosatx.com/

Contact:
Markus Warmuth, President and Chief Executive Officer
917-363-0113
https://www.linkedin.com/in/markus-warmuth-0b60909/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved